Compare Gilead Sciences, Inc. (GILD) vs Robinhood Markets, Inc. (HOOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Robinhood Markets, Inc. — how do they compare? Gilead Sciences, Inc. trades at $131.69 (market cap $163.51B), while Robinhood Markets, Inc. trades at $105.79 (market cap $103.73B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Robinhood Markets, Inc. pays none. Which is the better fit depends on your goals.
| GILD | HOOD | |
|---|---|---|
Market Cap | $163.51B | $103.73B |
Sector | Health | Technology |
52-Week High | $155.80 | $152.46 |
52-Week Low | $108.22 | $65.16 |
Enterprise Value | $178.05B | $104.93B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Robinhood (HOOD) trades at $110.23, down 2.84% on the day, with strong technical momentum indicated by bullish moving averages. The company reported robust 2025 results with $4.47B revenue and $1.88B net income, though Q1 2026 EPS slightly missed expectations. Recent news highlights expansion into financial services and positive analyst coverage, with 73% of analysts rating it a Buy.
The outlook remains positive given earnings growth and strategic initiatives, but risks include competitive pressures and market volatility. With a consensus price target of $112.07, near-term upside appears limited, yet long-term growth drivers like platform expansion support a constructive view for investors focused on financial technology growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →
